Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of RO7204239 in Facioscapulohumeral Muscular Dystrophy
2021-006255-34Phase 2Active
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing RO7204239 with Placebo (2 arms). Primary endpoint: Percent change from baseline in contractile muscle volume (CMV) of quadriceps femoris muscles. Started Jul 2022; status: active.
02
Drugs
emugrobart
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2021-006255-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006255-34.